Brief: Belite Bio Presents 18-Month Interim Data From A 24-Month Phase 2 Study Of Tinlarebant
25/04/2023 21:59
April 25 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO PRESENTED 18-MONTH INTERIM DATA FROM A 24-MONTH
PHASE
2 STUDY OF TINLAREBANT IN ADOLESCENT STARGARDT DISEASE AT THE
2023 ARVO MEETING
Source text for Eikon: ID:nGNX5qp7WL
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses